Close Menu

NEW YORK (GenomeWeb) – Somalogic and DeCode Genetics announced today that they are collaborating on a proteomic analysis of up to 40,000 of DeCode's patient samples.

The analysis will use Somalogic's SomaScan platform, which measures the levels of 5,000 proteins using the company's Somamer affinity reagents. According to the firms, Reykjavik-based DeCode will use the data gathered through this analysis for drug discovery and development work, while Boulder, Colorado-based Somalogic will use the findings to develop clinical applications of the SomaScan platform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.

The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.

One gene regulates hundreds of others to influence facial development, according to New Scientist.

In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.